JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

MannKind Corp

Fechado

SetorSaúde

3.99 0.76

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.93

Máximo

4.04

Indicadores-chave

By Trading Economics

Rendimento

5.7M

13M

Vendas

1.6M

78M

P/E

Médio do Setor

39.2

34.393

Margem de lucro

16.793

Funcionários

403

EBITDA

8.3M

27M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+124.49% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-316M

1.2B

Abertura anterior

3.23

Fecho anterior

3.99

Sentimento de Notícias

By Acuity

50%

50%

176 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 23:11 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 de ago. de 2025, 22:45 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 de ago. de 2025, 22:39 UTC

Ganhos

Great-West Lifeco Logs Lower 2Q Profit

5 de ago. de 2025, 21:32 UTC

Ganhos

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 de ago. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 de ago. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 de ago. de 2025, 23:19 UTC

Conversa de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 de ago. de 2025, 23:03 UTC

Conversa de Mercado
Ganhos

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 de ago. de 2025, 22:22 UTC

Ganhos

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 de ago. de 2025, 22:21 UTC

Ganhos

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 de ago. de 2025, 22:20 UTC

Ganhos

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 de ago. de 2025, 22:18 UTC

Ganhos

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 de ago. de 2025, 22:15 UTC

Ganhos

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 de ago. de 2025, 21:58 UTC

Ganhos

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 de ago. de 2025, 21:30 UTC

Ganhos

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 de ago. de 2025, 21:26 UTC

Ganhos

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 de ago. de 2025, 21:23 UTC

Ganhos

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 de ago. de 2025, 21:17 UTC

Ganhos

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

124.49% parte superior

Previsão para 12 meses

Média 8.8 USD  124.49%

Máximo 11 USD

Mínimo 7 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

176 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.